Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: Molecular mechanisms and pathology

Critical Reviews in Toxicology

Volumn 25, Issue 3, 1995, Pages 207-235

  Boelsterli, Urs A ^a   Zimmerman, Hyman J ^b   Kretz Rommel, Anke ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Acyl glucuronides; Drug induced hepatitis; Hypersensitivity; Immune mediated; Metabolic idiosyncrasy; NSAID; Protein adducts

Indexed keywords

ACETIC ACID DERIVATIVE; ALCLOFENAC; BENORILATE; BENOXAPROFEN; CLOMETACIN; DICLOFENAC; DIFLUNISAL; ETODOLAC; FENAMIC ACID DERIVATIVE; FENCLOFENAC; FENOPROFEN; IBUFENAC; IBUPROFEN; ISOXICAM; KEBUZONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; OXICAM DERIVATIVE; PHENYLBUTAZONE; PIROXICAM; PIRPROFEN; PROPIONIC ACID DERIVATIVE; PYRAZOLONE DERIVATIVE; SALICYLIC ACID DERIVATIVE; SULINDAC; SUPROFEN; TOLMETIN; UNINDEXED DRUG; ZOMEPIRAC;

ANTIGENICITY; CHOLESTASIS; DRUG HYPERSENSITIVITY; DRUG METABOLISM; HEPATITIS; HUMAN; IMMUNOTOXICITY; LIVER TOXICITY; NONHUMAN; REVIEW;

ANIMAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HEPATITIS, TOXIC; HUMAN; LIVER; SUPPORT, NON-U.S. GOV'T;

EID: 0029050333     PISSN: 10408444     EISSN: None     Source Type: Journal    
DOI: 10.3109/10408449509089888     Document Type: Article

References (245)

1. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors
2. Nonsteroidal anti-inflammatory drugs
3. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal drugs
4. Towards a better aspirin
5. The importance of stereochemistry in the clinical pharmacokinetics of the 2-arylpropionic acid nonsteroidal anti-inflammatory drugs
6. The metabolic chiral inversion of 2-arylpropionic acids — a novel route with pharmacological consequences
7. Stereoselective metabolism of antiinflammatory 2-arylpropionates
8. Inhibitory effects of non-steroidal antiinflammatory drugs on superoxide generation
9. Diclofenac inhibits monocyte superoxide productionex vivo in rheumatoid arthritis
10. Toxicity of the nonsteroidal antiinflammatory drugs
11. Renal toxicity of the nonsteroidal antiinflammatory drugs
12. Nonsteroidal anti-inflammatory drugs: effects on kidney function
13. Rac-Flurbiprofen is more ulcerogenic than its (S)-enantiomer
14. Another side effect of NSAIDs
15. Hepatitis and non-steroidal anti-inflammatory drugs
16. Rare adverse reactions to nonsteroidal antiinflammatory drugs
17. Update of hepatotoxicity due to classes of drugs in common clinical use: non-steroidal drugs, anti-inflammatory drugs, antibiotics, antihypertensives, and cardiac and psychotropic agents
18. Hepatotoxicity of nonsteroidal antiinflammatory drugs
19. Hepatic toxicity of nonsteroidal antiinflammatory drugs
20. Hepatotoxicity of antirheumatic drugs
21. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs
22. Liver disease associated with diclofenac, naproxen, and piroxicam
23. The role of non-steroidal anti-inflammatory drugs in acute liver injury
24. Safety of nonsteroidal anti-inflammatory drugs with respect to acute liver disease
25. Cinchophen (Atophan): a critical review
26. Cinchophen — is there a safe method of administration
27. Toxic and drug-induced hepatitis
28. FDA Arthritis Advisory Committee meeting
29. Phenylbutazone, further clinical evaluation
30. Ibufenac in the treatment of arthritis
31. Ibufenac (4-isobutylphenyl acetic acid)
32. Effects of non-narcotic analgesics on the liver
33. Phenylbutazone liver injury: a clinical pathologic survey of 23 cases and review of the literature
34. Hépatite chronique active à la clométacine et antigène HLA B8
35. Glafenine-associated hepatic injury: analysis of 38 cases and review of the literature
36. Diclofenac associated hepatitis
37. Hepatic injury associated with nonsteroidal anti-inflammatory drugs
38. Diclofenac-associated hepatic injury analysis of 181 cases
39. Diclofenac hepatitis
40. Hépatite au diclofenac
41. Diclofenac hepatitis
42. Hépatite aigue mortelle au cours d'un traitement par le diclofenac (Voltarene)
43. Fatal hepatitis associated with diclofenac
44. Diclofenac-induced hepatotoxicity
45. Diclofenac-associated hepatotoxicity
46. Diclofenac hepatitis
47. Reversible hepatitis associated with diclofenac
48. Diclofenac induced hepatitis — three cases with features of autoimmune chronic active hepatitis
49. Hépatite subfulminante mortelle au diclofénac
50. Adverse reactions to nonsteroidal antiinflammatory drugs
51. Hépatite au clométacine
52. Hépatite à la clométacine
53. Atteintes hépatiques après clométacine 6 cas dont 2 mortels
54. Pericholiangitie chez un adulte traité par clométacine
55. Hépatite à la clométacine
56. Chronic active hepatitis and grant multinucleated in adults treated with clometacin
57. Insuffisance rénale aigue et Hépatite lors d'un traitement par clométacine
58. Clometacineinduced hepatitis: a fatal crisis
59. Hépatite aigue à la clométacine. Interět du dosage des anticorps anti-noyaux et anti-muscle lisse
60. Serum antibodies against double-stranded DNA in chronic active hepatitis: an index of drug-induced liver disease
61. Un nouveau cas mortel de cirrhose d à la clométacine
62. Hépatites chroniques actives associées à des anticorps anti-DNA natif: fréquence de l'étiologie médicamenteuse
63. Severe reaction associated with sulindac administration
64. Sulindac and jaundice
65. Life-threatening hypersensitivity to sulindac
66. Hepatitis associated with use of sulindac in a child
67. Sulindac (Clinoril) and cholestatic jaundice
68. Sulindac (Clinoril) hepatitis
69. Sulindac hepatotoxicity
70. Cholestatic jaundice caused by sulindac
71. Serious adverse reactions associated with sulindac
72. Hépatite au sulindac: une observation avec revue des trois précédents
73. Hepatitis, toxic epidermal neurolysis and pancreatitis in association with sulindac therapy
74. Sulindac hepatotoxicity
75. Sulindac hepatotoxicity: effects of acute and chronic exposure
76. Sulindac hepatotoxicity: a case report and review
77. Encephalopathy associated with sulindac
78. Sulindac-induced Stevens Johnson toxic epidermal neurolysis syndrome
79. L'hépatotoxicité du sulindac: une nouvelle observation
80. Sulindac-associated hepatic injury—analysis of 91 cases reported to the food and drug administration
81. Jaundice associated with naproxen
82. Jaundice associated with naproxen
83. Cross hepatotoxicity between nonsteroidal anti-inflammatory drugs
84. Fulminant hepatitis following naproxen administration
85. Jaundice associated with naproxen
86. Liver involvement after treatment with naproxen
87. Naproxen e icteria
88. Fulminating hepatitis after treatment with naproxen and/or disulfiram
89. The problems and pitfalls of NSAID therapy in the elderly
90. Pharmacokinetics studies of benoxaprofen after therapeutic doses with a review of related pharmacokinetics metabolic studies
91. The pharmacokinetics of benoxaprofen in elderly subjects
92. Fatal cholestatic jaundice in elderly patients taking benoxaprofen
93. Jaundice associated with the use of benoxaprofen
94. Side effects of benoxaprofen
95. Side effects of benoxaprofen
96. Side effects of benoxaprofen
97. Fatal cholestatic jaundice in elderly patients taking benoxaprofen
98. Side effects of benoxaprofen
99. Hépatite au pirprofène
100. Pirprofen-induced fulminant hepatitis
101. Hépatites au pirprofène d'évolution favorable
102. Pirprofen-associated hepatic injury
103. Pirprofen and aspirin in rheumatoid arthritis: a double blind comparison study
104. Comparative efficacy of pirprofen and aspirin in rheumatoid arthritis
105. A double-blind comparison of aspirin and pirprofen in the treatment of rheumatoid arthritis
106. Inhibition of mitochondrial β-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal antiinflammatory drug
107. Granuloma and cholestatic hepatocellular injury associated with phenylbutazone. Report of two cases
108. Sarcoid reaction associated with phenylbutazone hypersensitivity
109. Phenylbutazone and hepatitis
110. Toxic effects of phenylbutazone on the cat
111. The protective effect of L-ornithine-L-aspartate on the liver in rats with drug-induced liver damage
112. Untersuchungen zum Mechanismus der Enzyminduktion. XV. Induktionsmuster und submikroskopische Veränderungen in der Leber nach Applikation von Phenylbutazone bei unterschiedlich alten Ratten
113. Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy
114. Prolonged cholestatic jaundice and leukopenia associated with piroxicam
115. Subacute hepatic necrosis induced by piroxicam
116. Hepatitis due to non-steroidal antiinflammatory agents: a new involved molecule, piroxicam (Feldene)
117. Fatal submassive necrosis of the liver associated with piroxicam
118. Emergency liver transplantation for fulminant hepatitis
119. Piroxicam hepatotoxicity
120. Severe cholestatic jaundice associated with piroxicam
121. Piroxicam-induced submassive necrosis of the liver
122. Fenclofenac
123. Voltarol: diclofenac sodium
124. Effects of aspirin and acetaminophen on the liver
125. Immunologic and metabolic basis of drug hypersensitivities
126. Drug-induced allergic hepatitis
127. Physiopathologie des hépatopathies médicamenteuses
128. In vitro oxidation of oxicam NSAIDs by a human liver cyto-chrome-P450
129. Cytochrome-P450TB (CYP2C) — a major monooxygenase catalyzing diclofenac 4α-hydroxylation in human liver
130. Diclofenac covalent protein binding is dependent on acylglucuronide formation and is inversely related to acute cell injury in cultured rat hepatocytes
131. A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs
132. Is there a rational basis for the different spectra of adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs)
133. Evidence for the role of reactive metabolites in hepatotoxicity of benoxaprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs)
134. Pharmacokinetics of nonsteroidal anti-inflammatory drugs
135. Towards safer nonsteroidal anti-inflammatory drugs
136. Glucuronidation of 2-arylpropionic acids pirprofen, flurbiprofen, and ibuprofen by liver microsomes
137. Taurine conjugation of fenclofenac in the dog
138. Biotransformation of diclofenac sodium (Voltaren) in animals and in man
139. Diclofenac sodium
140. Contrasting systemic stabilities of the acyl and phenolic glucuronides of diflunisal in the rat
141. New developments in glucuronidation research: report of a workshop on glucuronidation, its role in health and disease
142. Drug glucuronidation in humans
143. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate—glucuronosyl transferase glucuronidating carboxylic acid-containing drugs
144. Glucuronidation and its role in regulation of biological activity of drugs
145. Glucuronidation of drugs — a reevaluation of the pharmacological significance of the conjugates and modulating factors
146. Acyl glucuronides revisited — is the glucuronidation process a toxification as well as a detoxification mechanism
147. Acyl glucuronide conjugates: reactive metabolites of non-steroidal anti-inflammatory drugs
148. Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs
149. Acylation of albumin by 1-O-acyl glucuronides
150. Protein binding and stereoselectivity of nonsteroidal antiinflammatory drugs
151. Reversible binding of tolmetin, zomepirac, and their glucuronide conjugates to human serum albumin and plasma
152. Interactions between oxaprozin glucuronide and human serum albumin
153. Diclofenac sodium
154. Binding of suprofen to human serum albumin. Role of the suprofen carboxyl group
155. Stereoselective interactions of ketoprofen glucuronides with human plasma protein and serum albumin
156. Clinical pharmacokinetics of nonsteroidal anti-inflammatory drugs
157. Reactions of oxaprozin-1-O-acyl glucuronide in solutions of human plasma and albumin
158. Predictability of the covalent binding of acidic drugs in man
159. Irreversible binding of zomepirac to plasma proteinin vitro and
160. Covalent binding of zomepirac glucuronide to proteins: evidence for a Schiff base mechanism
161. Covalent binding of suprofen acyl glucuronide to albumin
162. Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry
163. Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins: retention of the glucuronic acid moiety in the adduct
164. Studies on the reactivity of acyl glucuronides. II. Interaction of diflunisal acyl glucuronide and its isomers with human serum albumin
165. In vitro irreversible binding of ketoprofen glucuronide to plasma proteins
166. Carprofen acyl glucuronides: stereoselective degradation and interaction with human serum albumin
167. Covalent binding of etodolac acyl glucuronide to albumin
168. Disposition and irreversible plasma protein binding of tolmetin in humans
169. Enhanced covalent binding of tolmetin to proteins in humans after multiple dosing
170. Studies on the reactivity of acyl glucuronides. IV. Covalent binding of diflunisal to tissues of the rat
171. Pharmacokinetics and irreversible binding of tolmetin and its glucuronic acid esters in the elderly
172. Covalent binding of diflunisal and probenecid to plasma protein in humans: persistence of the adducts in the circulation
173. Identification of macrophage cell-surface binding sites for cationized bovine serum albumin
174. Studies on the reactivity of acyl glucuronides. VIII. Generation of an antiserum for the detection of diflunisal-modified proteins in diflunisal-dosed rats
175. Studies on the reactivity of acyl glucuronides. V. Glucuronide-derived covalent binding of diflunisal to bladder tissue of rats and its modulation by urinary pH and beta-glucuronidase
176. Inhibition of UDP glucuronosyltransferase activity by possible transition state analogues in rat liver microsomes
177. Preliminary characterization of proteins to which benoxaprofen glucuronide binds irreversibly
178. Immunochemical detection of a major diclofenac-protein adduct in mouse liver: possible role in hepatotoxicity
179. Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac
180. Metabolic activation and immunochemical localization of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac
181. Selective protein adducts to membrane proteins in cultured rat hepatocytes exposed to diclofenac. Radiochemical and immunochemical analysis
182. Liver, lung, and spleen as target tissues for protein adduct formation associated with metabolism of the nonsteroidal antiinflammatory drug diclofenac
183. Covalent binding of diclofenac to plasma membrane proteins of the bile canaliculi in the mouse
184. Presence of covalently bound metabolites on rat hepatocyte plasma membrane proteins after administration of isaxonine, a drug leading to immunoallergic hepatitis in man
185. Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats
186. Classification of allergic reactions responsible for clinical hypersensitivity and disease
187. Immunopafhological mechanisms and clinical aspects of allergic reactions to drugs
188. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes
189. Purified hepatocytes can stimulate allospecific cytoloytic T lymphocytes in a mixed lymphocyte-hepatocyte culture
190. Expression of class I transplantation antigens
191. Cell-mediated hepatic injury in alcoholic liver disease
192. Cholestasis induces major histocompatibility complex class-I expression in hepatocytes
193. Immunogenicity of rat hepatocytesin vivo — effect of cholestasis-induced changes in major histocompatibility complex expression
194. Class I and class II major histocompatibility complex antigen expression on hepatocyes: a study in children with liver disease
195. HLA expression in liver disease
196. Can hepatocytes serve as activated immunomodulating cells in the immune response
197. Drug-induced hepatitis associated with anticytoplasmatic organelle autoantibodies
198. Xenogeneic antibodies against hepatocyte plasma membranes suppress bile secretion in rats
199. Cell-mediated cytotoxicity
200. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice
201. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis
202. Antibody mediated hepatocyte injury in methyl dopa induced hepatotoxicity
203. Cytotoxic activity of T cells and non-T cells from diclofenac-immunized mice against cultured syngenic hepatocytes exposed to diclofenac
204. Use of adult human hepatocytes in primary culture for the study of clometacin-induced immunoallergic hepatitis
205. Hépatites à la clométacine (Dupéran®). Etude rétrospective de 30 cas. Un modèle d'hépatite autoimmune médicamenteuse
206. Anti-cytosceletal autoantibodies: diagnostic significance for liver diseases, infections and systemic autoimmune diseases
207. Clometacine-induced hepatitis
208. Autoimmunity and liver disease
209. Genetic predisposition for the immunological features of chronic active hepatitis
210. MHC class II molecules and autoimmunity
211. Cross-reactions of anti-DNA autoantibodies with cell surface proteins
212. The role of autoantibodies in autoimmune disease
213. Characteristics of clometacin-induced hepatitis with special reference to the presence of anti-actin cable antibodies
214. Disposition and metabolism of benoxaprofen in laboratory animals and man
215. Relative toxicities of several nonsteroidal antiinflammatory compounds in primary cultures of rat hepatocytes
216. A study of the relative hepatotoxicityin vitro of the non-steroidal anti-inflammatory drugs ibuprofen, flurbiprofen and butibufen
217. Benoxaprofen-induced toxicity in isolated rat hepatocytes
218. Comparative cytotoxicity of non-steroidal antiinflammatory drugs in primary cultures of rat hepatocytes
219. Toxicity of diclofenac to isolated hepatocytes
220. Pharmacological studies of a new antiinflammatory drug, benoxaprofen. III. Effect on the hepatic drug-metabolizing enzyme system
221. The inhibition of hepatic microsomal drug metabolism in rats by non-steroidal anti-inflammatory drugs
222. The destruction of cytochrome P-450 by alclofenac: possible involvement of an epoxide metabolite
223. Effects of the nonsteroidal anti-inflammatory drug mefenamic acid on energy metabolism in the perfused rat liver
224. Lipid peroxidation in rat liver microsomes during naproxen metabolism
225. The stereoselective uptake of ibuprofen enantiomers into adipose tissue
226. Interactions of anti-inflammatory 2-arylpropionates (profens) with the metabolism of fatty acids:in vitro studies
227. Stereoselectivity in metabolic reactions of toxication and detoxication
228. Interrelationships between xenobiotic metabolism and lipid biosynthesis
229. Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial β-oxidation of fatty acids
230. Inhibition of hepatic drug-metabolizing enzymes by arachidonic acid
231. Leukotrienes in hepatocyte injury
232. Role of leukotrienes in acute inflammatory liver disease
233. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors
234. Conjugation pathways in liver disease
235. Biliary excretion of diflunisal conjugates in patients with T-tube drainage
236. Lymphocytes from hepatic inflammatory infiltrate kill rat hepatocytes in primary culture
237. Drug-specific T-cells derived from patients with drug-induced allergic hepatitis
238. Molecular mimicry of trifluoroacety lated human liver protein adducts by constitutive proteins and immunochemical evidence for its impairment in halothane hepatitis
239. Halothane metabolism — immunochemical evidence for molecular mimicry of trifluoroacetylated liver protein adducts by constitutive polypeptides
240. Halothane metabolism — the dihydrolipoamide acetyltransferase subunit of the pyruvate dehydrogenase complex molecularly mimics trifluoroacetyl-protein adducts
241. Pharmacologic studies with a new class of nonsteroidal anti-inflammatory agents — the oxicams — with special reference to piroxicam (Feldene®)